367 related articles for article (PubMed ID: 21031547)
1. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.
Cheung CK; Lo CM; Man K; Lau GK
Liver Transpl; 2010 Nov; 16(11):1314-23. PubMed ID: 21031547
[TBL] [Abstract][Full Text] [Related]
2. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
4. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome.
Rokuhara A; Tanaka E; Yagi S; Mizokami M; Hashikura Y; Kawasaki S; Kiyosawa K
J Med Virol; 2000 Dec; 62(4):471-8. PubMed ID: 11074476
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients.
Wong DK; Yuen MF; Yuan H; Sum SS; Hui CK; Hall J; Lai CL
Hepatology; 2004 Sep; 40(3):727-37. PubMed ID: 15349913
[TBL] [Abstract][Full Text] [Related]
6. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.
Matsuzaki T; Tatsuki I; Otani M; Akiyama M; Ozawa E; Miuma S; Miyaaki H; Taura N; Hayashi T; Okudaira S; Takatsuki M; Isomoto H; Takeshima F; Eguchi S; Nakao K
J Gastroenterol Hepatol; 2013 Jul; 28(7):1217-22. PubMed ID: 23432697
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
8. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection.
Caviglia GP; Abate ML; Tandoi F; Ciancio A; Amoroso A; Salizzoni M; Saracco GM; Rizzetto M; Romagnoli R; Smedile A
J Hepatol; 2018 Aug; 69(2):301-307. PubMed ID: 29621551
[TBL] [Abstract][Full Text] [Related]
10. Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis.
Lenci I; Marcuccilli F; Tisone G; Di Paolo D; Tariciotti L; Ciotti M; Guenci T; Perno CF; Angelico M
Dig Liver Dis; 2010 Aug; 42(8):578-84. PubMed ID: 20097143
[TBL] [Abstract][Full Text] [Related]
11. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
[TBL] [Abstract][Full Text] [Related]
13. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.
Lin LY; Wong VW; Zhou HJ; Chan HY; Gui HL; Guo SM; Wang H; Huang L; Bao SS; Xie Q; Chan HL
J Med Virol; 2010 Sep; 82(9):1494-500. PubMed ID: 20648602
[TBL] [Abstract][Full Text] [Related]
14. Change of hepatitis B virus DNA status in anti-HBc positive liver graft.
Kwon CH; Suh KS; Cho JY; Yi NJ; Jang JJ; Lee KU
Korean J Hepatol; 2006 Jun; 12(2):191-200. PubMed ID: 16804344
[TBL] [Abstract][Full Text] [Related]
15. Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts.
Niu Y; Chen X; Feng L; You H; Ren X; Liu H; Zheng J; Shen Z; Jia J
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):475-80. PubMed ID: 24835492
[TBL] [Abstract][Full Text] [Related]
16. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
19. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
[TBL] [Abstract][Full Text] [Related]
20. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
